Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25587310 | 1.00 | CCR2 (0.39) | CCR2PKMNPSR1SSTR1SSTR4 | |
| SCHEMBL8062901 | 0.83 | GAA (0.40) | LMNAPARP1 | |
| SCHEMBL29410344 | 0.83 | GAA (0.40) | LMNAPARP1 | |
| SCHEMBL24015488 | 0.81 | PTGDR2 (0.50) | NPSR1PTGDR2LMNAPARP1 | |
| SCHEMBL7526613 | 0.81 | PTGDR2 (0.50) | NPSR1PTGDR2LMNAPARP1 | |
| SCHEMBL18701560 | 0.74 | PDPK1 (0.56) | LMNA | |
| SCHEMBL2399818 | 0.72 | SLC6A2 (0.53) | TSHR | |
| SCHEMBL19531694 | 0.72 | DRD2 (0.47) | SSTR4DRD2HTR2ADRD3 | |
| SCHEMBL14335627 | 0.72 | HTT (0.63) | LMNA | |
| SCHEMBL28288067 | 0.72 | HTR2A (0.40) | LMNAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | CCR2 3166/4885PKM 2290/4885NPSR1 4691/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | CCR2 3220/4885PKM 2040/4885NPSR1 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.